Devices and methods for the delivery of molecular sieve materials for the formation of blood clots

Information

  • Patent Grant
  • 8257731
  • Patent Number
    8,257,731
  • Date Filed
    Wednesday, September 9, 2009
    14 years ago
  • Date Issued
    Tuesday, September 4, 2012
    11 years ago
Abstract
An apparatus for promoting the clotting of blood and controlling bleeding comprises a receptacle for retaining molecular sieve material in particulate form therein. A pad for controlling bleeding comprises a mesh structure and a rigid or semi-rigid support attached to the mesh structure to facilitate the application of pressure to the pad and the wound. A bandage applicable to a bleeding wound comprises a mesh structure and a flexible substrate attached to the mesh structure, the substrate being a cloth or plastic member that may be adhesively attached to cover a wound. In any embodiment, at least a portion of the receptacle or mesh structure is defined by a mesh having openings therein, and at least a portion of the particulate molecular sieve material is in direct contact with blood.
Description
BACKGROUND OF THE INVENTION

1. Field of the Invention


The present invention relates generally to blood clotting devices and, more particularly, to blood clotting materials, devices incorporating such materials, and methods for the delivery of such materials for use as bleeding control devices.


2. Description of the Related Art


Blood is a liquid tissue that includes red cells, white cells, corpuscles, and platelets dispersed in a liquid phase. The liquid phase is plasma, which includes acids, lipids, solublized electrolytes, and proteins. The proteins are suspended in the liquid phase and can be separated out of the liquid phase by any of a variety of methods such as filtration, centrifugation, electrophoresis, and immunochemical techniques. One particular protein suspended in the liquid phase is fibrinogen. When bleeding occurs, the fibrinogen reacts with water and thrombin (an enzyme) to form fibrin, which is insoluble in blood and polymerizes to form clots.


In a wide variety of circumstances, animals, including humans, can be wounded. Often bleeding is associated with such wounds. In some circumstances, the wound and the bleeding are minor, and normal blood clotting functions in addition to the application of simple first aid are all that is required. Unfortunately, however, in other circumstances substantial bleeding can occur. These situations usually require specialized equipment and materials as well as personnel trained to administer appropriate aid. If such aid is not readily available, excessive blood loss can occur. When bleeding is severe, sometimes the immediate availability of equipment and trained personnel is still insufficient to stanch the flow of blood in a timely manner.


Moreover, severe wounds can often be inflicted in remote areas or in situations, such as on a battlefield, where adequate medical assistance is not immediately available. In these instances, it is important to stop bleeding, even in less severe wounds, long enough to allow the injured person or animal to receive medical attention.


In an effort to address the above-described problems, materials have been developed for controlling excessive bleeding in situations where conventional aid is unavailable or less than optimally effective. Although these materials have been shown to be somewhat successful, they are sometimes not effective enough for traumatic wounds and tend to be expensive. Furthermore, these materials are sometimes ineffective in some situations and can be difficult to apply as well as remove from a wound.


Additionally, or alternatively, the previously developed materials can produce undesirable side effects. For example, prior art blood clotting material is generally a powder or a fine particulate in which the surface area of the material often produces an exothermic reaction upon the application of the material to blood. Oftentimes excess material is unnecessarily poured onto a wound, which can exacerbate the exothermic effects. Depending upon the specific attributes of the material, the resulting exothermia may be sufficient to cause discomfort to or even burn the patient. Although some prior art patents specifically recite the resulting exothermia as being a desirable feature that can provide clotting effects to the wound that are similar to cauterization, there exists the possibility that the tissue at and around the wound site may be undesirably impacted.


Furthermore, to remove such materials from wounds, irrigation of the wound is often required. If an amount of material is administered that causes discomfort or burning, the wound may require immediate flushing. In instances where a wounded person or animal has not yet been transported to a facility capable of providing the needed irrigation, undesirable effects or over-treatment of the wound may result.


Bleeding can also be a problem during surgical procedures. Apart from suturing or stapling an incision or internally bleeding area, bleeding is often controlled using a sponge or other material used to exert pressure against the bleed site and/or absorb the blood. However, when the bleeding becomes excessive, these measures may not be sufficient to stop the flow of blood. Moreover, any highly exothermic bleed-control material may damage the tissue surrounding the bleed site and may not be configured for easy removal after use.


Based on the foregoing, it is a general object of the present invention to provide devices for controlling bleeding and methods of their use that overcome or improve upon the prior art.


SUMMARY OF THE INVENTION

According to one aspect, the present invention resides in an apparatus for promoting the clotting of blood, thereby controlling bleeding. The apparatus comprises a receptacle for retaining molecular sieve material in particulate form therein. At least a portion of the receptacle is defined by a mesh having openings therein such that when the apparatus is applied to a bleed site, the particulate molecular sieve material comes into contact with blood through the openings.


Other aspects of the present invention include a pad for controlling bleeding and a bandage applicable to a bleeding wound. In both the pad and the bandage, there is a mesh structure and particles of molecular sieve material retained therein. In the pad embodiment, there is a rigid or semi-rigid support attached to the mesh structure to facilitate the application of pressure to the pad and the wound. In the bandage, there is a flexible substrate attached to the mesh structure, the substrate being a cloth or plastic member that may be adhesively attached to cover a wound. In any embodiment, the mesh structure may be defined by a plurality of members (strands, filaments, or strips of synthetic or natural material) interconnected and arranged to define openings. The openings are sized to allow contact to be maintained between the particles of the molecular sieve material and blood.


In yet another aspect of the present invention, a method of dressing a bleeding wound includes providing a molecular sieve material in particle form and retaining the material in a mesh structure, placing the mesh structure on a bleeding wound such that the molecular sieve material comes into contact with blood flowing from the wound, applying pressure to the mesh structure to ensure contact of the material with the blood, and removing the mesh structure from the wound.


An advantage of the present invention is that upon completion of the application of any of the devices of the present invention to a bleeding wound, the devices can be easily removed. In particular, because the zeolite material is in granule, bead, or pellet form and encased in a pouch or mesh structure, the material can be cleanly pulled away from the treated wound and disposed of. Accordingly, little or no irrigation of the wound is required to flush away remaining zeolite. In devices in which the pouch containing zeolite material is incorporated into an adhesive bandage, the device can be left on the wound for the amount of time necessary to cause clotting.


Another advantage is that the particlized form of the zeolite material allows the material to react less exothermically with blood. As the particle size increases (e.g., from fine to coarse), the surface area of the particles that the blood can come into contact with decreases. The porous nature of the material still allows liquid blood constituents to be wicked away to cause thickening of the blood, thereby facilitating the formation of clots. Because the particle surface area exposed to the blood is reduced, a less aggressive drawing of moisture from the blood is realized, which thereby tempers the exothermic effects experienced at the wound site.


Still another advantage of the present invention is that the proper dose of molecular sieve material can be readily applied to an open wound. Particularly when the device is a porous pouch containing zeolite material, the device can be readily removed from sterilized packaging and held directly at the points from which blood emanates to facilitate clotting of the blood without spilling powder or pellets outside the wound area. Guesswork, estimation, or calculation of the amounts of molecular sieve material for application to a bleeding wound is eliminated. Accordingly, little or no molecular sieve material is wasted.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a schematic representation of a blood clotting device of the present invention.



FIG. 2 is a side view of the blood clotting device of FIG. 1 illustrating the retaining of molecular sieve particles in a mesh container.



FIG. 3 is a side view of a pressure pad incorporating the molecular sieve particles encapsulated in a mesh container for pressure application to a bleeding wound.



FIG. 4 is a perspective view of a bandage incorporating the molecular sieve particles in a mesh container for application to a bleeding wound.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Disclosed herein are devices and methods for delivering materials to wounds to promote the clotting of blood and the dressing of the wounds. The devices generally comprise expedients or apparatuses that can be applied to bleeding wounds such that the materials contact the tissue of the wound to minimize or stop a flow of blood by absorbing at least portions of the liquid phases of the blood, thereby promoting clotting. One apparatus comprises a receptacle for retaining molecular sieve material in particulate form therein. At least a portion of the receptacle is defined by a mesh having openings therein, and at least a portion of the particulate molecular sieve material is in direct contact with blood through the openings.


The molecular sieve material used in the present invention may be a synthetic polymer gel, cellulosic material, porous silica gel, porous glass, alumina, hydroxyapatite, calcium silicate, zirconia, zeolite, or the like. Exemplary synthetic polymers include, but are not limited to, stylene-divinylbenzene copolymer, cross-linked polyvinyl alcohol, cross-linked polyacrylate, cross-linked vinyl ether-maleic anhydride copolymer, cross-linked stylene-maleic anhydride copolymer or cross-linked polyamide, and combinations thereof.


The molecular sieve material is preferably a zeolite. Other molecular sieve materials that may be used include, but are not limited to, faujasite. As used herein, the term “zeolite” refers to a crystalline form of aluminosilicate having the ability to be dehydrated without experiencing significant changes in the crystalline structure. The zeolite may include one or more ionic species such as, for example, calcium and sodium moieties. Typically, the zeolite is a friable material that is about 90% by weight calcium and about 10% by weight sodium. The calcium portion contains crystals that are about 5 angstroms in size, and the sodium portion contains crystals that are about 4 angstroms in size. The preferred molecular structure of the zeolite is an “A-type” crystal, namely, one having a cubic crystalline structure that defines round or substantially round openings.


The zeolite may be mixed with or otherwise used in conjunction with other materials having the ability to be dehydrated without significant changes in crystalline structure. Such materials include, but are not limited to, magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, a polysaccharide, combinations of the foregoing materials, and hydrates of the foregoing materials.


Zeolites for use in the disclosed applications may be naturally occurring or synthetically produced. Numerous varieties of naturally occurring zeolites are found as deposits in sedimentary environments as well as in other places. Naturally occurring zeolites that may be applicable to the compositions described herein include, but are not limited to, analcite, chabazite, heulandite, natrolite, stilbite, and thomosonite. Synthetically produced zeolites that may also find use in the compositions and methods described herein are generally produced by processes in which rare earth oxides are substituted by silicates, alumina, or alumina in combination with alkali or alkaline earth metal oxides.


Various materials may be mixed with, associated with, or incorporated into the zeolites to maintain an antiseptic environment at the wound site or to provide functions that are supplemental to the clotting functions of the zeolites. Exemplary materials that can be used include, but are not limited to, pharmaceutically-active compositions such as antibiotics, antifungal agents, antimicrobial agents, anti-inflammatory agents, analgesics (e.g., cimetidine, chloropheniramine maleate, diphenhydramine hydrochloride, and promethazine hydrochloride), bacteriostatics, compounds containing silver ions, and the like. Other materials that can be incorporated to provide additional hemostatic functions include ascorbic acid, tranexamic acid, rutin, and thrombin. Botanical agents having desirable effects on the wound site may also be added.


In one embodiment of the present invention, a device for facilitating the clotting of blood directly at a wound site is shown with reference to FIG. 1. The device is a permeable pouch that allows liquid to enter to contact blood clotting zeolite (or other molecular sieve) material retained therein. Sealed packaging (not shown) provides a sterile environment for storing the device until it can be used. The device, which is shown generally at 10 and is hereinafter referred to as “pouch 10,” comprises a screen or mesh 12 and zeolite particles 14 retained therein by the screen or mesh. The mesh 12 is closed on all sides and defines openings that are capable of retaining the zeolite particles 14 therein while allowing liquid to flow through. As illustrated, the mesh 12 is shown as being flattened out, and only a few zeolite particles 14 are shown.


The zeolite particles 14 are substantially spherical or irregular in shape (e.g., balls, beads, pellets, or the like) and about 0.2 millimeters (mm) to about 10 mm in diameter, preferably about 1 mm to about 7 mm in diameter, and more preferably about 2 mm to about 5 mm in diameter. In any embodiment (balls, beads, pellets, etc.), less particle surface area is available to be contacted by blood as the particle size is increased. Therefore, the rate of clotting can be controlled by varying the particle size. Furthermore, the adsorption of moisture (which also has an effect on the exothermic effects of the zeolite) can also be controlled.


The mesh 12 is defined by interconnected strands, filaments, or strips of material. The strands, filaments, or strips can be interconnected in any one or a combination of manners including, but not limited to, being woven into a gauze, intertwined, integrally-formed, and the like. Preferably, the interconnection is such that the mesh can flex while substantially maintaining the dimensions of the openings defined thereby. The material from which the strands, filaments or strips are fabricated may be a polymer (e.g., nylon, polyethylene, polypropylene, polyester, or the like), metal, fiberglass, or an organic substance (e.g., cotton, wool, silk, or the like).


Referring now to FIG. 2, the openings defined by the mesh 12 are dimensioned to retain the zeolite particles 14 but to accommodate the flow of blood therethrough. Because the mesh 12 may be pulled tight around the zeolite particles 14, the particles may extend through the openings by a distance d. If the zeolite particles 14 extend through the openings, the particles are able to directly contact tissue to which the pouch 10 is applied. Thus, blood emanating from the tissue immediately contacts the zeolite particles 14, and the water phase thereof is wicked into the zeolite material, thereby facilitating the clotting of the blood. However, it is not a requirement of the present invention that the zeolite particles protrude through the mesh.


To apply the pouch 10 to a bleeding wound, the pouch is removed from the packaging and placed on the bleeding wound. The zeolite particles 14 in the mesh 12 contact the tissue of the wound and/or the blood, and at least a portion of the liquid phase of the blood is adsorbed by the zeolite material, thereby promoting the clotting of the blood.


Another embodiment of the present invention is a pad which is shown at 20 with reference to FIG. 3 and is hereinafter referred to as “pad 20.” The pad 20 comprises the mesh 12, zeolite (or other molecular sieve) particles 14 retained therein by the mesh 12, and a support 22 to which pressure may be applied in the application of the pad 20 to a bleeding wound. The mesh 12, as above, has openings that are capable of retaining the zeolite particles 14 therein while allowing the flow of blood therethrough.


The mesh 12 is stitched, glued, clamped, or otherwise mounted to the support 22. The support 22 comprises an undersurface 24 against which the zeolite particles 14 are held by the container 12 and a top surface 26. The undersurface 24 is impermeable to the zeolite particles 14 (migration of the particles into the support 22 is prevented) and is further resistant to the absorption of water or other fluids. The top surface 26 is capable of having a pressure exerted thereon by a person applying the pad 20 to a bleeding wound or by a weight supported on the top surface 26. The entire support 22 is rigid or semi-rigid so as to allow the application of pressure while minimizing discomfort to the patient.


To apply the pad 20 to a bleeding wound, the pad 20 is removed from its packaging and placed on the bleeding wound. As with the pouch of the embodiment of FIGS. 1 and 2, the zeolite particles 14 are either in direct contact with the tissue of the wound or are in direct contact with the blood. Pressure may be applied to the wound by pressing on the top surface 26 with a hand or by placing a weight on the surface, thereby facilitating the contact between the zeolite particles 14 and the wound and promoting the adsorption of the liquid phase of the blood. The pad 20 (with or without a weight) may also be held onto the wound using a strapping device such as a belt, an elastic device, hook-and-loop material, combinations of the foregoing devices and materials, and the like.


Referring now to FIG. 4, another embodiment of the present invention is a bandage, shown at 50, which comprises zeolite particles 14 (or some other molecular sieve material) retained in a mesh 12 and mounted to a flexible substrate 52 that can be applied to a wound (for example, using a pressure-sensitive adhesive to adhere the bandage 50 to the skin of a wearer). The mesh 12 is stitched, glued, or otherwise mounted to a substrate 52 to form the bandage 50.


The substrate 52 is a plastic or a cloth member that is conducive to being retained on the skin of an injured person or animal on or proximate a bleeding wound. An adhesive 54 is disposed on a surface of the substrate 52 that engages the skin of the injured person or animal. Particularly if the substrate 52 is a non-breathable plastic material, the substrate may include holes 56 to allow for the dissipation of moisture evaporating from the skin surface.


In the preparation of zeolite material for the devices of the present invention (i.e., formation of the material into particle form), an initial level of hydration of the zeolite may be controlled by the application of heat to the zeolite material either before or after the material is formed into particles. However, it has also surprisingly been found that as the particle size of the zeolite is increased, the moisture content has less of a correlative effect on any exothermia produced as the result of mixing the particlized zeolite in blood. As such, formation of the zeolite material into the zeolite particles (shown at 14 in FIGS. 1-4), may be by extrusion, milling, casting, or the like.


Although this invention has been shown and described with respect to the detailed embodiments thereof, it will be understood by those of skill in the art that various changes may be made and equivalents may be substituted for elements thereof without departing from the scope of the invention. In addition, modifications may be made to adapt a particular situation or material to the teachings of the invention without departing from the essential scope thereof. Therefore, it is intended that the invention not be limited to the particular embodiments disclosed in the above detailed description, but that the invention will include all embodiments falling within the scope of the appended claims.

Claims
  • 1. A device for promoting the clotting of blood comprising: a pouch that is closed on all sides; anda molecular sieve in particle form which is retained in the pouch;wherein the pouch is composed of a mesh comprising a plurality of openings;wherein the molecular sieve particles are: sufficiently large to be retained by the mesh; andsufficiently small so that at least a portion of the particles can protrude through at least a portion of the openings of the mesh to make direct contact with blood outside of the pouch.
  • 2. The device of claim 1, wherein the molecular sieve comprises a zeolite.
  • 3. The device of claim 1, wherein the mesh comprises at least one of polyester, cotton, wool, or silk.
  • 4. The device of claim 1, wherein the particles have a diameter from about 2 mm to about 5 mm.
  • 5. The device of claim 1, further comprising a pharmaceutically-active composition which is mixed with, associated with, or incorporated into the molecular sieve.
  • 6. The device of claim 1, further comprising sterile packaging within which the pouch is stored until the pouch is used.
  • 7. A method of promoting the clotting of blood comprising: applying a device of claim 1 to a bleeding area of a mammal in need thereof.
  • 8. The method of claim 6, wherein the molecular sieve comprises an A-type zeolite.
  • 9. The method of claim 7, wherein the mesh comprises at least one of polyester, cotton, wool, or silk.
  • 10. The method of claim 7, wherein the molecular sieve particles are sufficiently large to reduce an exothermia produced by contact with blood.
  • 11. The method of claim 7, wherein the molecular sieve has a moisture content which is sufficiently high to reduce an exothermia associated with contact between blood and the molecular sieve, and wherein the moisture content is sufficiently low for the molecular sieve to be effective to promote the clotting of blood.
  • 12. The method of claim 6, further comprising an antimicrobial agent which is mixed with, associated with, or incorporated into the molecular sieve.
  • 13. The device of claim 2, wherein the molecular sieve comprises an A-type zeolite.
  • 14. The device of claim 1, further comprising an anti-inflammatory agent which is mixed with, associated with, or incorporated into the molecular sieve.
  • 15. The device of claim 1, further comprising an analgesic which is mixed with, associated with, or incorporated into the molecular sieve.
  • 16. The device of claim 1, further comprising an antibiotic which is mixed with, associated with, or incorporated into the molecular sieve.
  • 17. The device of claim 1, further comprising silver ions or a compound containing silver ions.
  • 18. The device of claim 1, further comprising magnesium sulfate, sodium metaphosphate, calcium chloride, dextrin, a polysaccharide, combinations of the foregoing materials, or hydrates of the foregoing materials.
  • 19. The device of claim 1, wherein the mesh is woven.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No. 11/054,918, filed Feb. 9, 2005, which is incorporated by references in its entirety herein.

US Referenced Citations (179)
Number Name Date Kind
2688586 Eberl et al. Sep 1954 A
2969145 Hannuer, Jr. Jan 1961 A
3122140 Crowe et al. Feb 1964 A
3181231 Breck May 1965 A
3189227 Hobbs et al. Jun 1965 A
3366578 Michalko Jan 1968 A
3386802 Michalko Jun 1968 A
3538508 Young Nov 1970 A
3550593 Kaufman Dec 1970 A
3723352 Warner et al. Mar 1973 A
3979335 Golovko et al. Sep 1976 A
4373519 Errede et al. Feb 1983 A
4374044 Schaefer et al. Feb 1983 A
4379143 Sherry et al. Apr 1983 A
4435512 Ito et al. Mar 1984 A
4460642 Errede et al. Jul 1984 A
4514510 Alexander Apr 1985 A
4524064 Nambu Jun 1985 A
4525410 Hagiwara et al. Jun 1985 A
4569343 Kimura et al. Feb 1986 A
4626550 Hertzenberg Dec 1986 A
4631845 Samuel et al. Dec 1986 A
4651725 Kifune et al. Mar 1987 A
4748978 Kamp Jun 1988 A
4822349 Hursey et al. Apr 1989 A
4828081 Nordstrom et al. May 1989 A
4911898 Hagiwara et al. Mar 1990 A
4938958 Niira et al. Jul 1990 A
4956350 Mosbey Sep 1990 A
5140949 Chu et al. Aug 1992 A
5146932 McCabe Sep 1992 A
5474545 Chikazawa Dec 1995 A
5486195 Myers et al. Jan 1996 A
5538500 Peterson Jul 1996 A
5556699 Niira et al. Sep 1996 A
5578022 Scherson et al. Nov 1996 A
5597581 Kaessmann et al. Jan 1997 A
5599578 Butland Feb 1997 A
D386002 Hinkle Nov 1997 S
5696101 Wu et al. Dec 1997 A
5716337 McCabe et al. Feb 1998 A
5725551 Myers et al. Mar 1998 A
5728451 Langley et al. Mar 1998 A
5766715 Garconnet Jun 1998 A
5788682 Maget Aug 1998 A
5801116 Cottrell et al. Sep 1998 A
5826543 Raymond et al. Oct 1998 A
5855570 Scherson et al. Jan 1999 A
5916511 Kotani et al. Jun 1999 A
5941897 Myers Aug 1999 A
5964349 Odagiri Oct 1999 A
5981052 Siguyama Nov 1999 A
5993964 Nakajima Nov 1999 A
6037280 Edwards et al. Mar 2000 A
6060461 Drake May 2000 A
6086970 Ren Jul 2000 A
6123925 Barry et al. Sep 2000 A
6159232 Nowakowski Dec 2000 A
6187347 Patterson et al. Feb 2001 B1
6203512 Farris et al. Mar 2001 B1
6372333 Sugiyama et al. Apr 2002 B1
6428800 Greenspan et al. Aug 2002 B2
6450537 Norris Sep 2002 B2
6475470 Kayane et al. Nov 2002 B1
6481134 Aledo Nov 2002 B1
6486285 Fujita Nov 2002 B2
6495367 Isogawa et al. Dec 2002 B1
6523778 Key et al. Feb 2003 B2
6573419 Naimer Jun 2003 B2
6590337 Nishikawa et al. Jul 2003 B1
6622856 Gallo et al. Sep 2003 B2
6630140 Grunstein Oct 2003 B1
6685227 Merry et al. Feb 2004 B2
6700032 Gray Mar 2004 B1
6701649 Brosi Mar 2004 B1
6745720 Rasner et al. Jun 2004 B2
6998510 Buckman et al. Feb 2006 B2
7125821 Xu et al. Oct 2006 B2
7371403 McCarthy et al. May 2008 B2
7429252 Sarangapani Sep 2008 B2
7595429 Hursey Sep 2009 B2
7604819 Huey et al. Oct 2009 B2
7825133 Yi Nov 2010 B2
7858123 Stucky Dec 2010 B2
7968114 Huey et al. Jun 2011 B2
8063264 Spearman et al. Nov 2011 B2
8114433 Huey et al. Feb 2012 B2
20020077653 Hudson et al. Jun 2002 A1
20020197302 Cochrum et al. Dec 2002 A1
20030133990 Hursey et al. Jul 2003 A1
20030175333 Shefer et al. Sep 2003 A1
20030176828 Buckman et al. Sep 2003 A1
20030199922 Buckman Oct 2003 A1
20030208150 Bruder et al. Nov 2003 A1
20030212357 Pace Nov 2003 A1
20040005350 Looney et al. Jan 2004 A1
20040038893 Ladner et al. Feb 2004 A1
20040166172 Rosati et al. Aug 2004 A1
20040169033 Kuibira et al. Sep 2004 A1
20040243043 McCarthy et al. Dec 2004 A1
20050023956 Kwak et al. Feb 2005 A1
20050058721 Hursey Mar 2005 A1
20050070693 Hansen et al. Mar 2005 A1
20050074505 Hursey Apr 2005 A1
20050107826 Zhu et al. May 2005 A1
20050118230 Hill et al. Jun 2005 A1
20050119112 Pfenninger et al. Jun 2005 A1
20050137512 Campbell et al. Jun 2005 A1
20050143689 Ramsey, III Jun 2005 A1
20050246009 Toner et al. Nov 2005 A1
20050248270 Ghosh et al. Nov 2005 A1
20050249899 Bonutti Nov 2005 A1
20060034935 Pronovost et al. Feb 2006 A1
20060078628 Koman et al. Apr 2006 A1
20060116635 Van Heughten Jun 2006 A1
20060121101 Ladizinsky Jun 2006 A1
20060141018 Cochrum et al. Jun 2006 A1
20060141060 Hursey et al. Jun 2006 A1
20060159733 Pendharkar et al. Jul 2006 A1
20060172000 Cullen et al. Aug 2006 A1
20060178609 Horn et al. Aug 2006 A1
20060193905 Ehringer et al. Aug 2006 A1
20060211965 Horn et al. Sep 2006 A1
20060211971 Horn et al. Sep 2006 A1
20060271094 Hudson et al. Nov 2006 A1
20060282046 Horn et al. Dec 2006 A1
20070016152 Karpowicz et al. Jan 2007 A1
20070031515 Stucky et al. Feb 2007 A1
20070065491 Huey et al. Mar 2007 A1
20070104768 Huey et al. May 2007 A1
20070104792 Jenkins May 2007 A1
20070134293 Huey et al. Jun 2007 A1
20070142783 Huey et al. Jun 2007 A1
20070154509 Wilcher et al. Jul 2007 A1
20070154510 Wilcher et al. Jul 2007 A1
20070154564 Stucky et al. Jul 2007 A1
20070160638 Mentkow et al. Jul 2007 A1
20070160653 Fischer et al. Jul 2007 A1
20070167971 Huey et al. Jul 2007 A1
20070251849 Lo et al. Nov 2007 A1
20070275073 Huey et al. Nov 2007 A1
20070276308 Huey et al. Nov 2007 A1
20070276345 Huey et al. Nov 2007 A1
20070281011 Jenkins et al. Dec 2007 A1
20080027365 Huey Jan 2008 A1
20080085300 Huey et al. Apr 2008 A1
20080097271 Lo et al. Apr 2008 A1
20080125686 Lo May 2008 A1
20080146984 Campbell et al. Jun 2008 A1
20080199539 Baker et al. Aug 2008 A1
20080206134 Lo et al. Aug 2008 A1
20080254146 Huey et al. Oct 2008 A1
20080254147 Huey et al. Oct 2008 A1
20080269658 Vinton et al. Oct 2008 A1
20080299226 Mentkow et al. Dec 2008 A1
20080317831 Lo Dec 2008 A1
20080319476 Ward et al. Dec 2008 A1
20090008261 Kotzeva et al. Jan 2009 A1
20090043268 Eddy et al. Feb 2009 A1
20090047366 Bedard et al. Feb 2009 A1
20090053288 Eskridge, Jr. et al. Feb 2009 A1
20090074880 Ladizinsky Mar 2009 A1
20090076475 Ross et al. Mar 2009 A1
20090112170 Wells et al. Apr 2009 A1
20090162406 Basadonna et al. Jun 2009 A1
20090186013 Stucky Jul 2009 A1
20090186071 Huey et al. Jul 2009 A1
20090232902 Liu et al. Sep 2009 A1
20090299253 Hursey Dec 2009 A1
20100035045 McAmish Feb 2010 A1
20100121244 Horn et al. May 2010 A1
20100209531 Stucky et al. Aug 2010 A2
20100228174 Huey et al. Sep 2010 A1
20100233248 Huey et al. Sep 2010 A1
20110015565 Hursey Jan 2011 A1
20110064785 Daniels Mar 2011 A1
20110268784 Huey Nov 2011 A1
20120004636 Lo Jan 2012 A1
20120070470 Pahari Mar 2012 A1
Foreign Referenced Citations (71)
Number Date Country
1223208 Jun 1987 CA
1970090 May 2007 CN
101104080 Jan 2008 CN
1114984 Mar 2008 CN
101541274 Sep 2009 CN
101687056 Mar 2010 CN
0 107 051 Sep 1983 EP
0 296 324 Dec 1988 EP
0 353 710 Feb 1990 EP
0 826 822 Mar 1998 EP
0 888 783 Jul 1999 EP
1 159 972 May 2001 EP
1 663 090 Jun 2006 EP
1 690 553 Aug 2006 EP
1 714 642 Oct 2006 EP
1 810 697 Jul 2007 EP
1 679 087 Jan 2010 EP
2 142 220 Jan 2010 EP
1 667 623 Nov 2010 EP
2 077 811 Nov 2010 EP
2 292 196 Mar 2011 EP
2 314 842 Jan 1998 GB
2259858 Aug 1999 GB
2 462 228 Feb 2010 GB
1135892 Jun 2010 HK
7088DELNP2009 Apr 2008 IN
241410 Jul 2010 IN
61145120 Jul 1986 JP
01-096558 Oct 1987 JP
2-45040 Feb 1990 JP
9-504719 May 1997 JP
2777279 Jul 1998 JP
10-337302 Dec 1998 JP
11-178912 Jul 1999 JP
11-332909 Jul 1999 JP
2002-530157 Sep 2002 JP
2003-66045 Mar 2003 JP
2004123651 Jul 2006 JP
2011 00164 Sep 2004 TR
WO 9505445 Feb 1995 WO
WO 9512371 May 1995 WO
WO 9640285 Dec 1996 WO
WO 9913918 Mar 1999 WO
WO 0030694 Jun 2000 WO
WO 0066086 Nov 2000 WO
WO 0182896 Aug 2001 WO
WO 0197826 Dec 2001 WO
WO 0230479 Apr 2002 WO
WO 02060367 Aug 2002 WO
WO 02074325 Sep 2002 WO
WO 03074566 Sep 2003 WO
WO 2005012493 Feb 2005 WO
WO 2005027808 Mar 2005 WO
WO 2005030279 Apr 2005 WO
WO 2005087280 Sep 2005 WO
WO 2005123170 Dec 2005 WO
WO 2006012218 Feb 2006 WO
WO 2006086557 Aug 2006 WO
WO 2006088912 Aug 2006 WO
WO 2006102008 Sep 2006 WO
WO 2006110393 Oct 2006 WO
WO 2007120342 Oct 2007 WO
WO 2008036225 Mar 2008 WO
WO 2008054566 May 2008 WO
WO 2008109160 Sep 2008 WO
WO 2008127497 Oct 2008 WO
WO 2008128149 Oct 2008 WO
WO 2008136806 Nov 2008 WO
WO 2008157536 Dec 2008 WO
WO 2009032884 Mar 2009 WO
WO 2009126917 Oct 2009 WO
Related Publications (1)
Number Date Country
20100121244 A1 May 2010 US
Continuations (1)
Number Date Country
Parent 11054918 Feb 2005 US
Child 12555876 US